Ameriprise
BLCM

Ameriprise’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Ameriprise’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,500
Closed -$298K – 3787
2019
Q2 		$298K Sell
17,500
-931
-5% -$25.2K ﹤0.01% 3485
2019
Q1 		$621K Buy
18,431
+8,238
+81% +$275K ﹤0.01% 3221
2018
Q4 		$298K Buy
10,193
+8,880
+676% +$394K ﹤0.01% 3353
2018
Q3 		$80K Buy
1,313
+7
+0.5% +$474 ﹤0.01% 3637
2018
Q2 		$96K Buy
+1,306
New +$102K ﹤0.01% 3571
2018
Q1 		– Sell
-1,397
Closed -$118K – 3717
2017
Q4 		$118K Buy
+1,397
New +$137K ﹤0.01% 3545
2017
Q2 		– Sell
-19,250
Closed -$2.38M – 3814
2017
Q1 		$2.38M Buy
19,250
+4,395
+30% +$576K ﹤0.01% 2503
2016
Q4 		$2.02M Buy
+14,855
New +$2.64M ﹤0.01% 2616

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Ameriprise's BLCM Position: Q3 2019 in Review

Ameriprise sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2019, closing a stake of 17,500 shares — an estimated $298K sold.

Ameriprise first reported a position in BLCM in Q4 2016 and held it in 8 quarters. The position peaked at $2.38M in Q1 2017. 67 funds tracked by Wall St. Rank hold BLCM as of Q3 2019.

  • Ameriprise reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Ameriprise sold 17,500 Bellicum Pharmaceuticals, Inc. shares in Q3 2019, an estimated $298K.
  • Ameriprise first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2016 and held it in 8 quarters.
  • Ameriprise's Bellicum Pharmaceuticals, Inc. position peaked at $2.38M in Q1 2017.
  • 67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2019.

Based on Ameriprise's 13F filing for Q3 2019, filed 14 Nov 2019.